Q-omics provides the consensus-scored ZNF292 profile across patient tissues and cancer cell-line models. ZNF292 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF292 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF292 RNA expression shows 21,868 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where ZNF292 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF292 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF292 survival associations across molecular data types. ZNF292 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF292 RNA expression–survival associations across cancer types. High ZNF292 expression shows unfavorable associations in LIHC, MESO and SARC, but favorable associations in KIRC, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF292 RNA expression.
This table summarizes ZNF292 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF292. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF292 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, CHOL, LUSC and LIHC. The KIRC box plot shows higher ZNF292 RNA expression in tumor versus normal tissue (log2 FC = +0.764, t-test p < 0.001).
This table shows molecular features associated with ZNF292 in patient tissues and cancer cell lines. In patient samples, ZNF292 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF292 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
